Aurora Cannabis Reports Revenues Of $75.5 Million For Q3, Doesn’t Provide Net Loss Figure

Aurora Cannabis (TSX: ACB) (NYSE: ACB) reported third quarter earnings after the bell today, electing to only file select data in the news release before the scheduled conference call. The firm reported net revenues of $75.5 million for the quarter, while not publishing an earnings per share or net loss figure. Adjusted EBITDA for the quarter was reported as being -$50.9 million for the period.

Net revenue overall was recorded as being $78.4 million, before provisions of $2.9 million were taken into account. Cannabis revenue during the quarter was $69.6 million. Of those revenues, $41.5 million was associated with the recreational cannabis market, $27.0 million was in the medical market, while the international medical cannabis market netted $4.0 million in revenues for Aurora.

In terms of associated expenses to achieve these revenues, Aurora has claimed that it is on the path to a run-rate of $40 – $45 million per quarter for selling, general and administrative expenses, despite spending a total of $80.1 million during the quarter in this expense category. Further expenditure data has not as of yet been provided.

In terms of Aurora’s cash position, the company reported $230.2 million as of March 31, an increase from December’s figure of $156.3 million. That increase was primarily driven by the company raising $206.4 million through its at-the-market offering and $22.0 million debt, which was partially offset by burning through $154.5 million during the quarter – which, unbelievably, was a significant quarter over quarter improvement.

Lastly, Aurora produced 36,207 kilograms of cannabis during the quarter, while only selling 12,729 kilograms.

Full financials have yet to be release by the company.

Aurora Cannabis last traded at $9.20 on the TSX.


Information for this briefing was found via Sedar and Aurora Cannabis. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Why the Market May Be Misreading Iran | David Woo

Why US Fertilizer Supply Could Matter a Lot More Now | Pat Varas – Sage Potash

Roscan Gold: Mali Discount Hits Kandiole PEA

Recommended

Antimony Resources Begins Technical Studies For Permitting Bald Hill Antimony Project

First Majestic Aims To Restart Production At Jerritt Canyon In H2 2027

Related News

BMO Struggling to Sell Aurora Cannabis’ TGOD Shares

Last night the Globe and Mail reported that a group of Investment Banks led by...

Friday, September 6, 2019, 12:24:09 AM

Aurora Cannabis Increases Offering To US$150 Million

It appears that Aurora Cannabis (TSX: ACB) (NYSE: ACB) has been somewhat successful in its...

Wednesday, November 11, 2020, 09:47:36 AM

Aurora Cannabis To Conduct 10 To 1 Reverse Split To Meeting Nasdaq Listing Requirements

In an effort to remain listed on the Nasdaq, Aurora Cannabis (TSX: ACB) has seen...

Wednesday, January 31, 2024, 08:22:26 AM

Aurora Cannabis Posts Record EBITDA But Free Cash Flow Remains In The Red

Aurora Cannabis Inc. (TSX: ACB) reported strong results in its fiscal Q2 2025 earnings, posting...

Wednesday, November 6, 2024, 09:15:46 AM

Aurora Cannabis Reiterates Guidance For Q1 2021

Aurora Cannabis (TSX: ACB) (NYSE: ACB) this morning reiterated guidance for the first quarter of...

Friday, October 30, 2020, 08:21:19 AM